WFSBP 2019 Final Program

44 Scientific Program / Wednesday, 5 June 2019 WFSBP 2019 WED T52: SCHIZOPHRENIA AND OTHER PSYCHOSIS: BASIC/CLINICAL S-46 SYMPOSIUM 08:15–09:45 East Meeting Room 16 Insulin resistance, dyslipidemia and immune response in early stages of severe mental illness: Targets for prevention of excess mortality Chair: Outi Mantere, Canada Co-Chair: Rodrigo Mansur, Canada 001 Offspring of parents with bipolar disorder (BD): Effects of obesity Rodrigo Mansur, Canada 002 Dysglycaemia and associated immune dysfunction in first episode psychosis Benjamin Perry, United Kingdom 003 Weight gain, insulin resistance and low-grade inflammation in first episode psychosis Jaakko Keinänen, Finland 004 Patterns of immune response in first episode psy- chosis Outi Mantere, Canada T1: ADDICTIVE DISORDERS S-47 SYMPOSIUM 08:15–09:45 East Meeting Room 9 Neuroimaging, genetics and the gut microbiota in addictive disorders Chair: Yanhui Liao, People‘s Republic of China Co-Chair: Mei Yang, People‘s Republic of China 001 The cognitive impairments and psychological well- being of the methamphetamine addicts Na Zhong, People‘s Republic of China 002 Genome-wide DNA methylation analysis of meth- amphetamine-induced psychosis and schizophrenia Huixi Dong, People‘s Republic of China 003 Gut microniota analysis in Methamphetamine- induced conditioned place preference rats Xiaojie Zhang, People‘s Republic of China 004 Disrupted small-world networks and reduced cortical thickness in chronic ketamine users Yanhui Liao, People‘s Republic of China T30: NEUROPHYSIOLOGY WS-06 WORKSHOP 08:15–09:45 East Meeting Room 7 Neurophysiology tools in psychiatry - clinical impact on diagnosis, prediction and intervention Chair: Oliver Pogarell, Germany Co-Chair: Nash Boutros, USA 001 Early intervention in psychiatric conditions: Role for neurophysiological measures Tomiki Sumiyoshi, Japan 002 Neurophysiology markers in depression and schizophrenia: Brain networks and oscillatory activity Oliver Pogarell, Germany 003 What is the impact of anti-craving medication on cue reactivity in alcoholic patients? Clémence Dousset, Belgium 004 Role of Standard EEG and MEG in guiding early intervention in Panic Disorder Nash Boutros, USA FC-04 FREE COMMUNICATION SESSION 08:15–09:45 East Meeting Room 11 Mood Disorders Chair: Alejo Corrales, Argentina 001 Cognitive outcomes with sequential monotherapy and adjunctive antidepressant treatment: Results from the Canadian Biomarker Integration Network in Depres- sion (CAN-BIND) study Trisha Chakrabarty, Canada S. J. McInerney, B. N. Frey, S. H. Kennedy, G. M. MacQueen, R. Milev, D. J. Müller, R. W. Lam 002 Stress and inflammation-related blood biomarkers of life adversities and effects of trauma-focused psycho- therapy in patients with treatment-resistant depression Elisabetta Maffioletti, Italy A. Cattaneo, M. Mazzelli, M. Bortolomasi, E. Zampieri, M. Gennarelli, A. Minelli 003 The tide has turned: Incidence of depression declined in community living young-old adults over one decade Hans Jeuring, The Netherlands E. Hoogendijk, H. Comijs, D. Deeg, A. Beekman, M. Huisman, M. Stek 004 Comparison of the effects of anticonvulsants on osteoclast formation and function Vinoomika Chandrasekaran, Australia J. M. Hodge, A. L. Stuart, J. A. Pasco, M. Berk, S. L. Brennan- Olsen, L. J. Williams